share_log

Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update

Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update

Rakovina Therapeutics Inc. 公佈2023年財務業績並提供公司最新情況
GlobeNewswire ·  04/26 20:38

VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company") a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and provided a corporate update.

不列顛哥倫比亞省溫哥華,2024年4月26日(GLOBE NEWSWIRE)——致力於推進基於新型DNA損傷反應技術的新癌症療法的生物製藥公司Rakovina Therapeutics Inc.(多倫多證券交易所股票代碼:RKV,“公司”)公佈了截至2023年12月31日的第四季度和財年的財務業績,並提供了公司最新情況。

2023 Highlights and Recent Developments

2023 年亮點和最新動態

  • On March 27, 2024 we announced a collaboration agreement with Dr. Artem Cherkasov granting Rakovina with exclusive access to the proprietary Deep Docking (trademarked) artificial intelligence ("AI") Platform for DNA-damage response targets. Using the Deep Docking platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures to evaluate their potential as targeted cancer drugs. The company then validates the activity using its established R&D infrastructure. This approach is innovative to developing new drug therapies that target DNA-damage response-related vulnerabilities that are common in many types of cancer.
  • On November 27, 2023, we announced the appointment of Prof. Artem Cherkasov, Senior scientist at the Vancouver Prostate Center and Canada Research Chair in Precision Cancer Drug Design to Rakovina Therapeutics' Scientific Advisory Board.
  • On November 20, 2023 we announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to Rakovina Therapeutics 's Scientific Advisory Board.
  • In June 2023, we published a manuscript in the Journal of Clinical Cancer Research reporting the characterization of a kt-3000 lead candidate with dual activity against PARP and HDAC enzymes as a potential treatment for Ewing sarcoma and other treatment-resistant cancers.
  • On April 19, 2023, we presented new preclinical in vitro and in vivo data demonstrating the potential of our kt-3000 series against treatment-resistant Ewing sarcoma, a rare childhood tumor, at the annual meeting of the American Association of Cancer Research (AACR).
  • On March 30, 2023, we announced the engagement of Red Cloud Securities and Proactive Investors Nort America Inc as part of our evolving strategy to improve trading liquidity and increase awareness of our next-generation cancer therapy development pipeline.
  • On March 22, 2023, we announced the receipt of $122,865 in non-dilutive finding from the National Research Council of Canada industrial Research Assistance Program.
  • On March 17, 2023, we presented new preclinical data describing progress in our lead optimization activities for our novel kt-3000 series at the EACR-AACR Basic and Translational Research Conference.
  • 2024年3月27日,我們宣佈與阿爾喬姆·切爾卡索夫博士簽訂合作協議,允許拉科維納獨家使用專有的深度對接(商標)人工智能(“AI”)平台,用於DNA損傷反應目標。使用由先進的人工智能算法提供支持的深度對接平台,Rakovina可以快速分析數十億個分子結構,以評估其作爲靶向抗癌藥物的潛力。然後,該公司使用其已建立的研發基礎設施對活動進行驗證。這種方法在開發針對許多類型癌症中常見的DNA損傷反應相關漏洞的新藥物療法方面具有創新性。
  • 2023年11月27日,我們宣佈任命溫哥華前列腺中心資深科學家、加拿大精準癌症藥物設計研究主席阿爾喬姆·切爾卡索夫教授爲Rakovina Therapeutics科學顧問委員會成員。
  • 2023年11月20日,我們宣佈任命曼徹斯特大學轉化神經腫瘤學系主任、阿斯利康公司前中樞神經系統癌症生物科學負責人佩特拉·哈默利克教授爲Rakovina Therapeutics科學顧問委員會成員。
  • 2023年6月,我們在《臨床癌症研究雜誌》上發表了一份手稿,報告了對PARP和HDAC酶具有雙重活性的kt-3000候選先導藥物的特性描述爲尤因肉瘤和其他耐藥癌症的潛在治療方法。
  • 2023 年 4 月 19 日,我們推出了新的臨床前研究 體外 在美國癌症研究協會(AACR)年會上,活體數據顯示了我們的kt-3000系列對抗耐藥尤因肉瘤(一種罕見的兒童腫瘤)的潛力。
  • 2023年3月30日,我們宣佈加入Red Cloud Securities和主動投資北美公司,這是我們不斷演變的戰略的一部分,旨在改善交易流動性並提高人們對下一代癌症療法開發渠道的認識。
  • 2023年3月22日,我們宣佈從加拿大國家研究委員會工業研究援助計劃獲得122,865加元的非稀釋資金。
  • 2023年3月17日,我們在EACR-AACR基礎與轉化研究會議上發佈了新的臨床前數據,描述了我們的新型kt-3000系列的先導藥物優化活動的進展。

Summary Financial Results for the fourth quarter and year ended December 31, 2023

截至2023年12月31日的第四季度和年度的財務業績摘要

At December 31, 2023, the Company had positive working capital of approximately $477,881.

截至2023年12月31日,該公司的正營運資金約爲477,881美元。

For the three and twelve months ending December 31, 2023 the Company reported a net loss of $722,733 and $2,612,925, respectively. Research and development operating expenses were $419,482 and $1,671,677 for the three and twelve months ended December 31, 2023, respectively. General and administrative expenses were $241,928 and $810,424 for the three and twelve months ending December 31, 2023, respectively. Total cash operating expenses related to research and development and general and administrative expenses for the three and twelve months ended December 31, 2022 were $488,414 and $1,816,715, respectively.

在截至2023年12月31日的三個月和十二個月中,該公司報告的淨虧損分別爲722,733美元和2612,925美元。截至2023年12月31日的三個月和十二個月中,研發運營支出分別爲419,482美元和1,671,677美元。截至2023年12月31日的三個月和十二個月中,一般和管理費用分別爲241,928美元和810,424美元。截至2022年12月31日的三個月和十二個月中,與研發相關的現金運營支出以及一般和管理費用分別爲488,414美元和1,816,715美元。

Selected Financial Information As at
December 31, 2023
$
Cash & cash equivalents 436,313
Working capital 477,881
Intangible assets 4,515,051
Total Assets 5,147,579
Total liabilities 1,487,743
Deficit (10,925,311)
Total equity 3,659,836
精選財務信息 截至目前
2023年12月31日
$
現金和現金等價物 436,313
營運資金 477,881
無形資產 4,515,051
總資產 5,147,579
負債總額 1,487,743
赤字 (10,925,311)
權益總額 3,659,836
Statements of net loss and comprehensive loss data: For the three months ended
December 31, 2023

$
For the year ended
December 31, 2023

$
Research & Development 419,482 1,671,677
General and administrative 241,928 810,424
Net loss and comprehensive loss (722,733) (2,612,925)
Basic and diluted income (loss) per share (0.01) (0.04)
Operating cash burn 488,414 1,816,715
Weighted average shares outstanding 69,904,462 69,848,394
淨虧損和綜合虧損數據報表: 在截至的三個月中
2023年12月31日
$
截至該年度
2023年12月31日
$
研究與開發 419,482 1,671,677
一般和行政 241,928 810,424
淨虧損和綜合虧損 (722,733) (2,612,925)
每股基本收益和攤薄收益(虧損) (0.01) (0.04)
運營現金消耗 488,414 1,816,715
加權平均已發行股數 69,904,462 69,848,394

Rakovina Therapeutics' financial statements as filed with SEDAR can be accessed from the Company's website at:

Rakovina Therapeutics向SEDAR提交的財務報表可從該公司的網站訪問,網址爲:

About Rakovina Therapeutics Inc.

關於 Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at .

Rakovina Therapeutics Inc.專注於開發基於新型DNA損傷反應技術的新型癌症治療方法。該公司已經建立了一條新的DNA損傷反應抑制劑產品線,目標是將一種或多種候選藥物推進人體臨床試驗,並獲得加拿大衛生部、美國食品藥品監督管理局和類似國際監管機構的癌症新療法的上市許可。更多信息可以在以下網址找到。

Additional Information

附加信息

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所既未批准也未批准本新聞稿的內容。多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Notice regarding forward-looking statements:

關於前瞻性陳述的通知:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at .

本新聞稿包括有關公司及其各自業務的前瞻性陳述,其中可能包括但不限於與公司擬議業務計劃有關的陳述和其他陳述。通常,但並非總是如此,前瞻性陳述可以通過使用 “計劃”、“預期”、“預期”、“計劃”、“打算”、“考慮”、“預期”、“相信”、“提議” 等詞語或此類詞語和短語的變體(包括負面變體)來識別,或者聲明某些行動、事件或結果 “可能”、“會”、“可能” 或 “將” 被採取、發生或實現。此類聲明基於公司管理層當前的預期。本新聞稿中討論的前瞻性事件和情況可能不會在某些特定日期之前發生,也可能根本不會發生,並且由於影響公司的已知和未知風險因素和不確定性,包括醫療器械行業的風險、經濟因素、監管因素、總體股票市場以及與增長和競爭相關的風險,可能會有重大差異。 儘管公司試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的重大差異的重要因素,但可能還有其他因素導致行動、事件或結果與預期、估計或預期的不同。任何前瞻性陳述都無法保證。除非適用的證券法要求,否則前瞻性陳述僅代表其發佈之日,並且公司沒有義務公開更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。 請讀者參閱公司在SEDAR上提交的最新文件,以更全面地討論所有適用的風險因素及其潛在影響,其副本可通過公司的個人資料頁面訪問,網址爲。

Contact:

聯繫人:

Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
403-613-1453
Email: info@rakovinatherapeutics.com
Investor Relations Contact
IR@rakovinatherapeutics.com
Media Contact
MEDIA@rakovinatherapeutics.com
Rakovina Therapeutics Inc.
大衛海曼
首席財務官
403-613-1453
電子郵件:info@rakovinatherapeutics.com
投資者關係聯繫人
IR@rakovinatherapeutics.com
媒體聯繫人
MEDIA@rakovinatherapeutics.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論